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ABSTRACT 39 
 40 
The cyclopalladation of a series of symmetric diimines with the formula (RC6H4CHNZ)2, where Z = 41 
CH2 or (CH2)2OCH2 and R = p-Cl, p-OMe, p-NO2, and o-Cl, is described. Optimal conditions to 42 
obtain the dimetalated compounds were found to be palladium(II) acetate, in toluene, at 60 °C and with 43 
a reaction time of 2−4 h. The reactivity of the dimetalated compounds with monodentate, bidentate, and 44 
bis(monodentate) Lewis bases was also studied. The cytotoxic activity of some selected compounds was 45 
evaluated against a panel of adenocarcinoma cell lines (colon HCT116 and breast MCF7 and MDA-46 
MB231). Compounds containing the fragment NCH2CH2OCH2CH2OCH2CH2N exhibited a 47 
remarkable cytotoxic activity in the three cancer cells assayed, but complexes containing the 48 
NCH2CH2N fragment showed no activity. It seems that the length and flexibility of the central saturated 49 
chain in the imine molecule, as well as its lipophilicity and hydrophilicity, explain the different 50 








  59 
INTRODUCTION 60 
 61 
The cyclometalation reaction is a well-known process that represents one of the classic ways to activate 62 
C−H bonds in heterosubstituted organic molecules.1 The first cyclometalated compounds were reported 63 
in the mid 1960s,2 and since then, this reaction has extensively been studied and has gained a great 64 
interest given the application of metallacycles in many areas, which include organic synthesis, catalysis, 65 
design of metallomesogens, asymmetric synthesis, resolution of racemic ligands, C−H bond activation, 66 
or in the synthesis and reactivity of organometallic complexes with biologically relevant ligands.3 67 
The use of cyclopalladated compounds as antitumor drugs is one of the most interesting applications of 68 
these derivatives. It has been postulated that these compounds can be an alternative to platinum-based 69 
drugs, owing to the similar chemistry between palladium and platinum.4 Palladium complexes show a 70 
higher kinetic lability that can be modulated by means of the use of chelating ligands such as 71 
cyclometalated organic derivatives. Recently, a considerable number of palladacycles have been 72 
evaluated for cytotoxic activity against a variety of cancer cell lines with remarkable results.5 73 
For biological activity, an important factor in the design of metal-containing anticancer agents is to 74 
provide an optimal balance between lipophilicity and reactivity. The lipophilicity of a drug candidate, 75 
which can be tuned with the appropriate choice of functional groups, is important because it dictates the 76 
degree of cellular uptake, whereas optimal reactivity kinetics ensure that a significant amount of metal 77 
can bind to DNA or other cellular targets within the biologically relevant time frame. 78 
Studies on platinum(II) compounds show that their activity relies mostly on specific interactions with 79 
DNA, leading to damage and ultimately to cell death. Previous to the metal−DNA adduct formation, the 80 
departing ligands (generally a halide leaving group) play an integral role in influencing the aquation rate, 81 
therefore improving aqueous solubility or hydrolytic stability of the complex inside the cell. 82 
It has been proposed that polymetallic complexes can present a stronger electrostatic recognition of 83 
DNA, in comparison with monomeric species, due to the fact that polynuclear species are generally 84 
highly positively charged in solution. The compound [{trans-PtCl (NH3)2}2 - (μ-trans - {Pt - 85 
(NH3)2(NH2(CH2)6NH2)2})]4+ (BBR3464) is a trinuclear platinum drug highly cytotoxic both in vitro 86 
and in vivo (see Chart 1), and its activity derives from the flexible adducts that form with DNA. This 87 
compound completed a phase I trial, but failed phase II probably due to instability in blood and rapid 88 
drug degradation in vivo.6 Recently a new family of dinuclear platinum(II) complexes containing bis-89 
pyridyl-based ligands has been described, and its cytotoxicity was determined against the human ovarian 90 
carcinoma cell line A2780.7 91 
Cyclometalation involves the coordination of one metal atom per organic ligand in the majority of cases. 92 
However, a relatively large number of doubly cyclometalated compounds derived from diamines, 93 
diimines, bis(oximes), bis(hydrazones), azobenzenes, bis(iminophosphoranes), azines, pyrazines, bis-94 
(pyrimidines), bis(pyridines), bis(pyrazoles), and bis-(imidazoles) are known.8 95 
Here we describe the cyclopalladation of a series of symmetric diimines with the formula 96 
(RC6H4CH=NZ)2, where Z = CH2 or (CH2)2OCH2), with the aim of obtaining dipalladated 97 
compounds containing the fragment NCH2CH2N or N(CH2)2O(CH2)2O(CH2)2N, which exhibit 98 
differences in length, flexibility, lipophilicity, and hydrophilicity. The present paper also addresses the 99 
study of these new polynuclear compounds as antitumor agents. Additionally, electrophoretic DNA 100 
migration studies in the absence and in the presence of topoisomerase I have been performed, in order to 101 
gain insights into the biological behavior of the synthesized compounds. 102 
 103 
  104 
RESULTS AND DISCUSSION 105 
 106 
Synthesis of Compounds. The symmetric diimines (RC6H4CH=NZ)2 [Z = CH2, R = p-Cl (1), p-OMe 107 
(2); Z = (CH2)2OCH2, R = p-Cl (3), p-OMe (4), p-NO2 (5), and o-Cl (6)] were synthesized by 108 
combining the appropriate, aldehyde and symmetric diamine in a 2:1 molar ratio, following the 109 
previously described procedures.9 The 1H and 13C{1H} NMR spectra of diimines 1−6 exhibited only 110 
one set of signals, which was attributed to the (E,E) isomer, as confirmed by 1H−1H NOESY 111 
experiments. The cyclometalation of ligands 1−6 can produce mono- or dicyclopalladated compounds 112 
by C−H activation. Therefore, some studies on the cyclometalation of diimine 1 were conducted, in 113 
order to optimize the preparation of the dimetalated derivative 1a. Solvent screening (toluene, acetone, 114 
glacial acetic acid, and chloroform) was performed at different temperatures and reaction times. 115 
Synthesis in acetic acid and chloroform led to the dimetalated derivative 1a with modest yields due to 116 
the formation of significant amounts of the monometalated complex. Optimal conditions to obtain the 117 
dimetalated compound 1a were found to be in toluene, at 60 °C, and with a reaction time of 2−4 h, using 118 
palladium(II) acetate as a metalating agent. When these conditions were applied to the diimines 2 and 3, 119 
the acetato-bridging dimetalated compounds 2a and 3a were also prepared through double 120 
intramolecular σ(Csp2−H) bond activation (see Scheme 1). Compounds 4a, 5a, and 6a were obtained 121 
using acetic acid as solvent (see Scheme 1 and Experimental Part). Compounds 1a−3a and 4a−6a were 122 
obtained in 77−55% and 40−31% yield, respectively (see Experimental Part and Supporting 123 
Information). 124 
All attempts to metalate ligands (p-NO2-C6H4CH=NCH2)2 and (o-Cl-C6H4CH=NCH2)2 failed. The 125 
main problem seems to be the hydrolysis of these ligands. In some cases the formation of complexes 126 
such as [Pd(en)2]2+ and [Pd(en)-(OAc)]+ was detected by mass spectrometry, suggesting that the 127 
formation of these species makes the hydrolysis of these diimines easier. 128 
Acetato-bridged derivatives 1a−6a were characterized by mass spectra, elemental analyses, and infrared 129 
spectra. The 1H and 13C{1H} NMR spectra of these compounds produced a complex pattern of 130 
uninterpretable signals, and these data are not included in the experimental part. This could be attributed 131 
to the lability of the acetato ligands, the cis−trans rearrangements of the complexes, or some equilibria 132 
involving species of different nuclearity.10 133 
Characterization of compounds 1a−6a in solution was conducted by analysis of their dinuclear 134 
derivatives obtained in an NMR tube by addition of pyridine-d5 to a CDCl3 solution of these 135 
compounds. This reaction afforded the expected dinuclear compounds [{Pd(O2CMe)(py-136 
d5)(RC6H3CH=NZ-κC,κN)}2] [Z = CH2, R = p-Cl (1c), p-OMe (2c); Z = (CH2)2OCH2, R = p-Cl (3c), 137 
p-OMe (4c), p-NO2 (5c), and o-Cl (6c)]. The high-field shift of the aromatic protons of the palladated 138 
ring in the proton NMR spectra of compounds c indicates the cis disposition of the pyridine relative to 139 
the metalated carbon atom.11 Despite the simplification of the spectra when adding pyridine-d5 to a 140 
CDCl3 solution of the acetato-bridging compounds a, in some instances some minor species were 141 
observed by NMR spectra. These minor compounds are also dicyclometalated complexes, because in all 142 
cases the H2 aromatic proton appears high-field shifted at δ = 6.0−6.2 ppm. 143 
The MALDI TOF(+) mass spectra of 1a−6a led to the dinuclear monocation [M1 − AcO]+, where M1 144 
corresponds to one dimetalated moiety in which the two palladium atoms are linked by two acetato 145 
bridging ligands. The tetrapalladated fragment [M2 − AcO]+, where M2 designates two dimetalated 146 
moieties bound by four acetato bridging ligands, was observed only for the acetato-bridged complexes 147 
1a and 2a. However, the possibility of the bridged complexes being polymeric in the solid state cannot 148 
be ruled out, as the aforementioned peaks may arise from fragmentation of a polymeric structure. 149 
The cyclopalladated compounds 1a−6a were easily converted by a metathesis reaction with LiCl into the 150 
chloridobridged cyclopalladated analogues 1b−6b. These chloridobridged derivatives were characterized 151 
by mass spectra and infrared spectra. The MALDI TOF(+) mass spectra of 1b and 2b revealed the 152 
tetrapalladated monocation [M2 − Cl]+. Nevertheless, the polynuclear nature of these complexes cannot 153 
be discarded. These new compounds were very insoluble in common solvents, which precluded their 154 
purification by recrystallization or column chromatography. Unlike their acetato-bridged counterparts, 155 
1H NMR spectra of a chloroform-d solution of the chlorido-bridged derivatives in the presence of an 156 
excess of py-d5 showed just one compound with the formula [{Pd(Cl)(py-d5)(RC6H3CH=NZ-157 
κC,κN)}2] [Z = CH2, R = p-Cl (1d), p-OMe (2d); Z = (CH2)2OCH2, R = p-Cl (3d), p-OMe (4d), p-158 
NO2 (5d), and o-Cl (6d)]. The different behavior of chlorido- and acetato-bridged compounds versus 159 
pyridine can be related with the higher lability of acetate ligands. 160 
Suitable crystals for X-ray analysis of 1d·3(CDCl3) and 2d·2(CDCl3) were obtained by slow 161 
evaporation of deuterated chloroform solutions of 1b or 2b in the presence of an excess of deuterated 162 
pyridine-d5. Both structures present a dicyclopalladated unit containing a dianionic bis-[C,N] chelating 163 
ligand. The coordination sphere of each palladium atom is completed by one chlorido ligand plus one 164 
deuterated pyridine molecule in the cis position relative to the metalated carbon. The metal center 165 
exhibits a slightly distorted square-planar geometry owing to the C−Pd−N bite angle, and the 166 
palladacycle is nearly coplanar with the phenyl metalated ring. The bond distances and bond angles of 167 
the metallacycle are similar to those reported for related complexes.12 Due to steric reasons, the 168 
pyridine ring is orientated at dihedral angles of 60−90° with respect to the metalated phenyl ring. The 169 
NCH2CH2N framework shows a zigzag arrangement with N−C−C−N torsion angles close to 180°, and 170 
the palladacycles are practically parallel. 171 
The structures of the two compounds reveal diverse intermolecular interactions. The crystal packing of 172 
1d shows chains that propagate along the [110] vector, which are consolidated by π−π interactions 173 
between each palladacycle and its neighboring phenyl metalated ring. The crystal packing of complex 174 
2d is stabilized by C−H···π weak intermolecular interactions generating a chain along the 175 
crystallographic a axis. 176 
Halido-bridged complexes 1b−6b could be cleanly converted to dinuclear compounds 177 
[{Pd(Cl)(PPh3)(RC6H3CH=NZ- κC,κN)}2] [Z = CH2, R = p-Cl (1e), p-OMe (2e); Z = (CH2)2OCH2, 178 
R = p-Cl (3e), p-OMe (4e), p-NO2 (5e), and o-Cl (6e)] upon addition of triphenylphosphane in a 179 
PPh3/dicyclometalated unit molar ratio of 2:1. Cyclopalladated derivatives 1e−6e were characterized by 180 
mass spectra, elemental analysis, infrared spectra, and 1H, 13C{1H}, and 31P{1H} NMR. The aromatic 181 
protons of the palladated ring appear to be high-field shifted in the proton NMR spectrum, showing the 182 
cis disposition between the phosphane and the metalated carbon.13 183 
Suitable crystals for X-ray analysis of 1e·4(CDCl3) were obtained by slow evaporation of a deuterated 184 
chloroform solution of complex 1e. The distances between palladium and the coordinated atoms are 185 
similar to those reported.14 The phosphorus and nitrogen atoms adopt a trans arrangement, the metal 186 
center exhibits a slightly distorted square-planar geometry owing to the C−Pd−N bite angle, and the 187 
palladacycle is nearly coplanar with the phenyl metalated ring. The palladium−nitrogen bond distance is 188 
in the range 2.099−2.133 Å. In contrast, the palladium−iminic nitrogen bond in the pyridinecontaining 189 
derivatives is in the range 1.995−2.071 Å, in agreement with the larger trans influence of 190 
triphenylphosphane. 191 
The NCH2CH2N framework in 1e shows a zigzag arrangement with N−C−C−N torsion angles close to 192 
180°, and the palladacycles are practically parallel. As shown in complex 2d the crystal packing in 1e is 193 
stabilized by C−H···π interactions, generating a chain along the crystallographic a axis. 194 
Reactivity of Compounds 1b and 3b toward Bidentate Lewis Bases. Considerable efforts were made 195 
to explore the reactivity of the chlorido-bridged complexes 1b and 3b with potentially bidentate and 196 
bis(monodentate) Lewis bases. The reactions of complex 1b with a variety of rigid and flexible ligands, 197 
such as NH2(CH2)2O(CH2)2O(CH2)2NH2, trans-Ph2PCH=CHPPh2, NH2CH2(CHOH)CH2NH2, or 198 
4,4′- bipyridine, were unsuccessful, as extremely insoluble solids were formed in all cases. The lack of 199 
solubility of these products suggested the possibility of a polymeric structure. Similar results were 200 
obtained when using the dicyclopalladated derivative 3b. However, one exception was found. Treatment 201 
of 3b with the highly flexible ligand 2,2′-(ethylenedioxy)bis-(ethylamine) for 4 h at room temperature in 202 
chloroform afforded compound 3f, which was characterized by mass spectra, infrared spectra, and 1H 203 
and 13C{1H} NMR spectra (see Chart 2). 204 
In the 1H NMR spectra of 3f, coordination of the Lewis base to the metal center caused deshielding of 205 
the aliphatic protons of the bridging ligand with respect to the free Lewis base. This fact was further 206 
supported by MS and IR spectra. In the mass spectra the dipalladated fragments [M − Cl]+ were 207 
detected, but there was no evidence of tetranuclear fragments or higher order aggregates. It should be 208 
noted that the 1H−1H NOESY spectrum of complex 3f revealed the existence of cross-peaks between 209 
the CH7=N proton and all the aliphatic protons of the adjacent N−CH2 8−CH2 9−O−CH2 10 moiety. 210 
Similarly, the aromatic proton H2 showed correlations with all protons of the NH2−CH2 11−CH2 211 
12−O−CH2 13 aliphatic chain. The fact that the imine proton is close in space to CH2 10, and H2 to 212 
CH2 13, evidenced that the molecule adopts a somewhat folded conformation, which seems to fit with a 213 
dinuclear structure. 214 
Theoretical calculations on the systems [({Pd(Cl){4-ClC6H3CH=N(CH2)2OCH2-κC,κN}}2{μ-215 
NH2(CH2)2O-(CH2)2O(CH2)2NH2-κN:κN′})n] (n = 1 and 2) were performed in order to provide 216 
complementary insights into structure 3f. Molecular dynamics simulations led to the most stable 217 
conformations of the dinuclear and the tetranuclear forms (n = 1 and 2, respectively), which were then 218 
reoptimized at the DFT level. In accordance with 2D NMR studies, calculations revealed that both 219 
model systems adopt folded conformations. Optimized geometries for the dinuclear and tetranuclear 220 
forms are shown in Figures 4 and 5, respectively. Additionally, H···H distances between the imine 221 
proton and its adjacent aliphatic chain (CH2 8−CH2 9−O−CH2 10), as well as the H···H distances 222 
between the H2 atom and its neighboring NH2−CH2 11−CH2 12−O−CH2 13 chain, are generally 223 
consistent with the accepted range of NOE interactions (2−5 Å). 224 
DFT calculations predicted that in a vacuum at 0 K the tetranuclear form is slightly more stable, as the 225 
energy increment corresponding to the formation of the tetranuclear complex from two molecules of the 226 
dinuclear compound (ΔEdimerization) is −0.4 kcal/mol. The addition of solvent effects increases the 227 
stability of the dinuclear form. Thus, in chloroform, ΔEdimerization is +4.9 kcal/mol. The large size of 228 
the tetranuclear system precluded us from making a frequency calculation; hence a comparison of free 229 
energies could not be made at the DFT level. 230 
In order to make an estimation of ΔGdimerization, we repeated the calculations using the PM6 231 
semiempirical method, which gives ΔEdimerization values very close to DFT (−0.6 kcal/mol in 232 
vacuum). The PM6 thermodynamic corrections result in a further stabilization of the dinuclear form. 233 
Thus, on combining the DFT energies with the semiempirical thermodynamic corrections, the resulting 234 
ΔGdimerization is 17 kcal/mol in chloroform, although this value should be regarded as approximate. 235 
In conclusion, theoretical and experimental evidence (mass spectrum and NOESY experiment) suggest 236 
that in solution compound 3f could adopt a folded dinuclear structure.  237 
  238 
BIOLOGICAL STUDIES 239 
 240 
Human colon (HCT116) and breast (MCF7 and MDAMB231) cancer cell lines were used to test the 241 
cytotoxic activity of cyclometalated palladium(II) complexes derived from diimines 1 and 3 containing 242 
the NCH2CH2N and the NCH2CH2OCH2CH2OCH2CH2N fragments, respectively. For comparison 243 
purposes the free ligands 1 and 3 and cisplatin were evaluated under the same experimental conditions in 244 
the three cell lines selected. The IC50 values resulting from an average of two experiments are shown in 245 
Table 1, and the effects of 3a, 3b, 3e, and 3f on the growth of the assayed cell lines are displayed in 246 
Figure 6. 247 
No cytotoxic activity was observed either for the free ligands 1 and 3 or for the cyclopalladated 248 
complexes 1a, 1b, and 1e, containing the NCH2CH2N fragment. 249 
Interestingly, the metalated palladium(II) complexes 3a, 3b, 3e, and 3f featuring the 250 
NCH2CH2OCH2CH2OCH2CH2N fragment exhibited a remarkable cytotoxic effectiveness in the three 251 
cellular lines assessed (Table 1), and most of these compounds exhibited lower IC50 values than that of 252 
cisplatin. The best inhibition of cell growth proliferation was provided for compounds 3a in HCT116 253 
colon and MCF7 breast adenocarcinoma cell lines, while compound 3e was the most effective against 254 
MDA-MB231 breast cancer cells. 255 
A great number of factors such as lipophilicity, stability in biological medium, molecular size, 256 
flexibility, and influx or efflux through cellular membranes may account for the different cytotoxicity of 257 
transition metal compounds. The dramatic increase in cytotoxicity observed for the compounds 258 
containing the fragment NCH2CH2OCH2CH2OCH2CH2N upon the complexes bearing the 259 
NCH2CH2N fragment in the three cancer cells assayed can be racionalized in terms of the flexibility, 260 
lipophilicity, and hydrophilicity provided by each fragment in the diimine ligand. 261 
The influence of flexibility on the cytotoxicity of the complexes is in agreement with the proposal that 262 
polymetallic complexes derive their activity through the flexible adducts that they form with DNA.6 On 263 
the other hand, hydrophilicity can be related with hydrogen-bonding capability of the oxygenated 264 
fragments, which may favor solubility in the biological media as well as interactions with biomolecular 265 
targets.15 Finally, the similarity in the IC50 values of compounds 3a and 3b, contaning acetato- or 266 
chlorido-bridged ligands, can be understood if we consider that, in the biological media, these products 267 
may easily be transformed into the aqua cation [Pd(CN)(H2O)2]+, being (CN) the cyclometalated 268 
imine.16 269 
Recently, it has been reported a high cellular uptake of structurally different palladium-coordinated 270 
compounds [thiosemicarbazone Pd(II) compounds, planaramine Pd(II) complexes, trinuclear Pt−Pd−Pt 271 
analogues of BBR3464, etc.) by several human cancer cell lines.17 In addition, it was found that within 272 
a series of complexes the highest cellular accumulation is in line with the highest cytotoxic 273 
activity.17a,b 274 
The binding of 1a, 1b, 1e, 3a, 3b, 3e, and 3f to DNA was studied by their ability to modify the 275 
electrophoretic mobility of the supercoiled closed circular (ccc) and the open circular (oc) forms of 276 
pBluescript SK+ plasmid DNA. The ccc form usually moves faster due to its compact structure. Figure 277 
7 shows the electrophoretic mobility of pBluescript SK+ plasmid DNA incubated with the studied 278 
palladium(II) compounds at 37 °C in an unwinding experiment at increasing concentrations (from 2.5 to 279 
200 μM). To provide a basis for comparison, incubation of DNA with cisplatin and ethidium bromide 280 
(EtBr) was also performed using the same concentrations and conditions. 281 
As expected, cisplatin greatly altered the electrophoretic mobility of pBluescript SK+ plasmid DNA at 282 
2.5 μM, but for EtBr only a very slight decrease in the electrophoretic mobility of DNA was detected at 283 
25 to 100 μM concentration. Organopalladium(II) compounds 1a, 1b, 1e, 3a, 3b, 3e, and 3f were less 284 
efficient than cisplatin in removing the supercoils from DNA, although some were more cytotoxic than 285 
cisplatin itself. Hence, these results suggested that DNA might not be the exclusive target biomolecule 286 
for this kind of compound.6 287 
On increasing the concentration of 1a, 3a, 3b, and 3f, a significant change in plasmid DNA mobility is 288 
detected. The migration rate of the supercoiled band decreased until it comigrated with the nicked 289 
relaxed band. In these titration experiments, the coalescence point (defined as the amount of palladium 290 
complex required for complete removal of all supercoils from DNA) occurred at 25 μM (lane 5). 291 
Unwinding of negative supercoiled DNA to positive supercoiled DNA was observed in the 292 
electrophoretogram at higher concentrations for 1a (lanes 6 and 7) and for 3a, 3b, and 3f (lane 6). The 293 
DNA was destroyed and no longer visible18 at concentrations higher than 100 μM. The same effect of 294 
coalescence and positive supercoiling was observed for cisplatin (Figure 7, bottom). Interestingly, 295 
complex 3a, exhibiting lower IC50 values in HCT116 colon and MCF7 breast human adenocarcinoma 296 
cells, turned out to be one of the most efficient in retarding the plasmid DNA migration. 297 
It is noteworthy that noncytotoxic cyclopalladated compounds (i.e., complexes 1a and 1b, IC50 values 298 
>100 μM) induced significant changes on DNA mobility. It is assumed that in the conditions of the gel 299 
mobility assay (40 μM/mL, 0.8 μg DNA) noncytotoxic cyclopalladated compounds such as 1a and 1b 300 
interacted to some extent with DNA in a similar way to that of cisplatin. On the other hand, compounds 301 
bearing the triphenylphosphane ligand, such as 1e (IC50 >100 μM, in the three lines assessed) and 3e 302 
(IC50 = 5.5 μM in MDA-MB231), did not modify plasmid DNA migration, pointing out another 303 
mechanism of action or another biomolecular target from that of cisplatin. 304 
Although intercalation has been traditionally associated with molecules containing fused bi- or tricyclic 305 
ring structures, atypical intercalators might be more prevalent than originally thought.19 In order to 306 
ascertain whether compound 3e, which has a similar potency to that of cisplatin against MDA-MB231 307 
breast cancer cells, could be a DNA intercalator, a topoisomerase-based gel assay was performed.20 308 
Supercoiled pBluescript plasmid DNA was incubated in the presence of topoisomerase I and increasing 309 
concentrations of compound 3e. Results presented in Figure 8 showed that 3e does not prevent 310 
unwinding of DNA by the action of topoisomerase I, indicating that this compound is neither an 311 
intercalator nor an inhibitor of topoisomerase I.21 312 
In conclusion, all the palladated compounds containing the fragment NCH2CH2OCH2CH2OCH2CH2N 313 
exhibited a remarkable cytotoxic effectiveness. Interestingly, complex 3a was found to inhibit cell 314 
growth proliferation of the MCF7 breast cell line at a level ca. 4 times higher than that of cisplatin. In 315 
contrast, all the complexes containing the NCH2CH2N fragment showed no cytotoxic activity. The 316 
remarkable difference in the activity of these two series of similar compounds shows the importance of 317 
the flexibility, hydrophilicity, and lipophilicity to the cytotoxic activity of coordination complexes. 318 
All the cyclopalladated complexes, with the exception of 1e and 3e, featuring a triphenylphosphane 319 
ligand, modify the helicity of plasmid DNA, although to a lesser extent than cisplatin, pointing to 320 
another mechanism of action or a biomolecular target different from cisplatin. 321 
Further studies are in progress centered on both the mechanistic elucidation (cell cycle arrest, induction 322 
of apoptosis, etc.) of the cytotoxic activity of these polynuclear palladium(II) complexes and the 323 
development of more potent polymetalated derivatives. 324 
  325 
EXPERIMENTAL PART 326 
 327 
Materials and Methods. All the operations were carried out in air, unless otherwise stated. All 328 
chemicals were obtained from commercial sources and used as received. Solvents were distilled and 329 
dried before use.22 The synthesis and chracterization data of the biologically nonactive compounds 330 
1a−e and 2a−e are given in the Supporting Information. 331 
MALDI TOF (+) spectra were registered using dithranol (DTH), 2,5-dihydroxybenzoic acid (DHB), or 332 
trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile (DCTB) as a matrix. Chemical 333 
ionization (CI) (+) mass spectra were recorded using ammonia as the reagent gas. Low-resolution ESI 334 
(+) spectra were acquired utilizing a mixture of H2O/CH3CN (1:1, v/v) as the eluent. As for the MS 335 
notation, M1 refers to one dimetalated moiety linked by two X bridging ligands, M2 designates two 336 
dimetalated moieties bound by four X bridging ligands, and NN represents 2,2′-(ethylenedioxy)bis-337 
(ethylamine). 338 
Infrared spectra were obtained using KBr pellets. The solvent used in the 1H and 13C{1H} NMR 339 
experiments was CDCl3 (99.9%), and the references were SiMe4 [δ(1H) = 0.00 ppm)] or the solvent 340 
peak [δ(13C) = 77.00], respectively. The 31P{1H} NMR spectra were registred in CDCl3, CHCl3, or 341 
acetone-d6 and were referenced to P(OMe)3 [δ(31P) = 140.17 ppm]. The chemical shifts (δ) are given in 342 
ppm, and the coupling constants (J) in Hz. In the characterization section of each product the assignment 343 
of signals detected in the NMR spectra refers to the labeling patterns presented in Scheme 1 and Chart 2. 344 
X-ray Diffraction. In all cases, a prismatic crystal was selected and mounted on a diffractometer fitted 345 
with an image plate detector. Intensities were collected with graphite-monochromatized Mo Kα 346 
radiation. Structures were solved by Patterson synthesis [adduct 1d·3(CDCl3)] or direct methods 347 
[1e·4(CDCl3) and 2d·2(CDCl3)] using the SHELXS computer program23 and refined by full-matrix 348 
leastsquares method with the SHELX97 computer program.24 The crystals of sample 1e, susceptible to 349 
solvent loss, were coated in perfluoroalkyl ether, and X-ray determinations were measured at 203 K. As 350 
samples 1d·3(CDCl3) and 2d·2(CDCl3) were air stable, X-ray analyses were performed at ambient 351 
temperature. 352 
CCDC nos. 995314 (2d), 995315 (1e), and 995316 (1d) contain the supplementary crystallographic data 353 
for this paper. These data are also available free of charge via www.ccdc.cam.ac.uk/cgi-bin/catreqcgi or 354 
from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 355 
1223-336-033; e-mail: deposit@ ccdc.cam.ac.uk). 356 
Synthesis of Compounds a. 3a: A Schlenk tube loaded with ligand 3 (503 mg, 1.28 mmol) and 357 
palladium(II) acetate (583 mg, 2.60 mmol) was evacuated and flushed with nitrogen three times. Freshly 358 
distilled toluene (25 mL) was added to the flask. The crude reaction mixture was maintained at 60 °C for 359 
5 h under stirring, after which time the metallic deposit formed was removed by filtration. Filtrate was 360 
concentrated under reduced pressure and next subjected to flash column chromatography over silica gel 361 
(Φ = 3 cm × 23.5 cm) eluting with 100:2 chloroform/methanol, gradually increasing the polarity to 362 
100:4 and 100:6. The second eluted band was collected to give 3a after solvent removal. A deep-orange 363 
solid precipitated via addition of diethyl ether (5 mL), which was subsequently filtered and air-dried 364 
(507 mg, 55% yield). IR (cm−1): 1613 (CN st), 1561 (COO as st), 1417 (COO sym st). MS-MALDI 365 
TOF (+) (DHB), m/z: 660.7 (calcd 660.9) [M1 − AcO]+. Anal. Calcd for (C24H26Cl2N2O6Pd2)n [Mr 366 
(722.22 × n)]: C 39.91, H 3.63, N 3.88. Found: C 39.5, H 3.5, N 3.7. 367 
4a: Aldimine 4 (511 mg, 1.33 mmol) and palladium(II) acetate (597 mg, 2.66 mmol) were brought into a 368 
Schlenk flask, evacuated for 10 min, and finally flushed with nitrogen. To this was added glacial acetic 369 
acid (40 mL). The reaction mixture was heated to 60 °C and maintained at this temperature for 6 h. After 370 
this time, the resulting mixture was then concentrated to dryness and subjected to column 371 
chromatography over silica gel (Φ = 3 cm × 24 cm) using a chloroform/methanol solvent system. Eluent 372 
polarity was gradually increased from 100:2, to 100:3, to 100:5. 4a was obtained as a deep yellow 373 
powder after solvent removal and addition of diethyl ether (5 mL). The product was collected by 374 
filtration and air-dried (377 mg, 40% yield). IR (cm−1): 1609 (C=N st), 1569 (COO as st), 1413 (COO 375 
sym st), 1264 (CH3−O−Car as st), 1035 (CH3−O−Car sym st). MS-MALDI TOF (+) (DHB), m/z: 488.2 376 
(calcd 488.2) [M1 – 2 AcO − Pd]+. Anal. Calcd for (C26H32N2O8Pd2)n [Mr (713.38 × n)]: C 43.77, H 377 
4.52, N 3.93. Found: C 43.2, H 4.4, N 3.7. 378 
5a: To a Schlenk tube were charged ligand 5 (470 mg, 1.13 mmol) and palladium(II) acetate (500 mg, 379 
2.23 mmol). An evacuation/backfill cycle was applied three times. Glacial acetic acid (25 mL) was then 380 
added to the flask. The crude reaction mixture was held at 60 °C for 5 h under stirring, after which time 381 
the solvent was removed in vacuo. The residue was redissolved in a 100:5 chloroform/methanol mixture 382 
and soon afterward passed through a short silica plug (Φ = 3 cm × 4.5 cm). The silica was washed with 383 
the same solvent system until the washings went colorless. The resulting reddish filtrate was 384 
immediately reduced under vacuum since complex 5a slowly darkens in a 100:5 chloroform/methanol 385 
solution. Filtration must be performed at once to prevent decomposition to palladium black. Addition of 386 
diethyl ether (5 mL) yielded a maroon-colored solid, which was subsequently filtered and air-dried (260 387 
mg, 31% yield). IR (cm−1): 1618 (C=N st), 1563 (COO as st), 1516 (NO2 as st), 1415 (COO sym st), 388 
1339 (NO2 sym st). MS-MALDI TOF (+) (DTH), m/z: 683.0 (calcd 683.2) [M1 − AcO]+. Anal. Calcd 389 
for (C24H26N4O10Pd2)n [Mr (743.32 × n)]: C 38.78, H 3.53, N 7.54. Found: C 38.6, H 3.7, N 7.5. 390 
6a: Aldimine 6 (256 mg, 0.65 mmol) and palladium(II) acetate (290 mg, 1.29 mmol) were combined in 391 
glacial acetic acid (40 mL), and the resulting mixture was allowed to stir at room temperature for a 392 
couple of days. After this period, an orange solid corresponding to the acetato-bridged complex 6a was 393 
observed. The mixture was then concentrated to dryness and subjected to column chromatography over 394 
silica gel (Φ = 2.5 cm × 19 cm) using a 100:2 chloroform/ methanol solvent system. Eluent polarity was 395 
gradually increased to 100:3, 100:4, and 100:5. The colored band led to the desired precipitate after 396 
solvent removal followed by addition of diethyl ether (ca. 10 mL). The product was finally separated by 397 
filtration and airdried (149 mg, 32% yield). IR (cm−1): 1605 (CN st), 1562 (COO as st), 1411 (COO 398 
sym st). MS-MALDI TOF (+) (DTH), m/z: 661.1 (calcd 660.9) [M1 − AcO]+. Anal. Calcd for 399 
(C24H26Cl2N2O6Pd2)n [Mr (722.22 × n)]: C 39.91, H 3.63, N 3.88. Found: C 39.5, H 3.5, N 3.8. 400 
Synthesis of Compounds b. 3b: To a suspension of acetatobridged complex 3a (174 mg, 0.12 mmol) in 401 
acetone (30 mL) was added an excess of lithium chloride (47 mg, 1.12 mmol). The resulting 402 
mixture was stirred at room temperature for 1 day. As the solution turned yellow, an off-white 403 
precipitate ascribed to lithium salts formed. The reaction crude was filtered and reduced in vacuo. Upon 404 
subjecting the mixture to flash column chromatography (SiO2, Φ = 3.5 cm × 2 cm), using acetone as an 405 
eluent, a colored band developed in the column. This fraction was collected and the solvent removed 406 
under reduced pressure. Addition of a small volume of diethyl ether (ca. 5 mL) rendered pure 3b as a 407 
cream-colored solid (121 mg, 74% yield). IR (cm−1): 1612 (C=N st). MS-MALDI TOF (+) (DTH), m/z: 408 
637.0 (calcd 636.9) [M1 − Cl]+. 409 
4b: Complex 4b was synthesized by adding lithium chloride (47 mg, 1.11 mmol) to a suspension of 410 
acetato-bridged complex 4a (130 mg, 0.09 mmol) in acetone (30 mL). The resultant mixture was 411 
intensely stirred at ambient temperature for 1 day. The reaction crude was then concentrated under 412 
reduced pressure. Addition of diethyl ether led to a pale yellow precipitate, which was filtered off and 413 
repeatedly washed with deionized water (6 × 5 mL) and a small portion of chilled acetone (0.5 mL) (92 414 
mg, 76% yield). IR (cm−1): 1608 (C=N st), 1267 (CH3−O−Car as st), 1032 (CH3−O−Car sym st). MS-415 
MALDI TOF (+) (DHB), m/z: 629.2 (calcd 629.0) [M1 − Cl]+. 416 
5b: Halido-bridged complex 5b was prepared by combining acetatobridged compound 5a (34 mg, 0.023 417 
mmol) with lithium chloride (13 mg, 0.31 mmol) in acetone (25 mL) at room temperature. The resulting 418 
mixture was allowed to stir for 2 h, and then volatiles were reduced under vacuum. Upon addition of 419 
diethyl ether, an intense yellow solid precipitated, which was recovered by filtration, washed repeatedly 420 
with water (6 × 4 mL) and a small portion of chilled ethanol (2 mL), and finally dried in air (27 mg, 421 
85% yield). IR (cm−1): 1616 (C=N st), 1516 (NO2 as st), 1339 (NO2 sym st). MS-MALDI TOF (+) 422 
(DTH), m/z: 659.0 (calcd 658.9) [M1 − Cl]+. 423 
6b: Acetato-bridged complex 6a (100 mg, 0.07 mmol) was dissolved in chloroform (50 mL) after 1 h of 424 
vigorous stirring. A solution of lithium chloride (23 mg, 0.55 mmol) in acetone (10 mL) was stirred for 425 
5 min and next poured into the chloroform solution. The resultant yellow mixture was allowed to stand 426 
at ambient temperature for approximately 45 min, during which time the solution lightened to an 427 
extremely pale yellow. Also lithium acetate precipitated out, which was eliminated by filtration and 428 
discarded. The filtrate was evaporated under vacuum, to yield the expected product upon addition of 429 
diethyl ether (ca. 5 mL). The yellow solid obtained was filtered off and air-dried (86 mg, 92% yield). IR 430 
(cm−1): 1609 (CN st). MSMALDI TOF (+) (DHB), m/z: 636.9 (calcd 636.9) [M1 − Cl]+. 431 
Synthesis in Solution of Compounds c and d. A solution constituted by the acetato-bridged or chlorido 432 
cyclopalladated compound (ca. 10 mg) in deuterated chloroform (approximately 0.7 mL) was treated 433 
with deuterated pyridine (ca. 2 drops) and shaken for a few seconds. The resultant solution became 434 
lighter, which indicated the quantitative formation of the corresponding dinuclear derivative. Due to the 435 
rapid exchange between the coordinated and the free pyridine-d5, carbon NMR signals of the 436 
coordinated pyridine-d5 were not observed for compounds 2c, 3d, 5c, 5d, 6c, and 6d. 437 
Characterization Data. 3c: 1H NMR (400 MHz, CDCl3, 298 K): 7.87 (s, 1 H, CH7=N), 7.21 (d, JHH = 438 
8.0 Hz, 1 H, H5), 7.00 (dd, JHH = 8.0 Hz, JHH = 1.9 Hz, 1 H, H4), 6.12 (d, JHH = 1.9 Hz, 1 H, H2), 439 
3.81 (apparent t, J ≈ 4−5 Hz, 2 H, CH2 9−O), 3.65 (s, 2 H, CH2 10−O), 3.65−3.64 (m, 2 H, CH2 8−N), 440 
1.87 (s, 3 H, CH3−COO). 13C{1H} NMR (101 MHz, CDCl3, 298 K): 178.0 (s, CH3−COO), 176.0 (s, 441 
CH7=N), 158.1 (s, C1), 152.8 (apparent t, J ≈ 26−29 Hz, o-Cpy‑d5), 145.5 (s, C6), 138.3−137.7 (m, p-442 
Cpy‑d5), 136.0 (s, C3), 132.6 (s, C2), 128.4 (s, C5), 125.2 (apparent t, J = 23 Hz, m-Cpy‑d5), 124.6 (s, 443 
C4), 70.6 (s, CH2 10−O), 68.6 (s, CH2 9−O), 58.8 (s, CH2 8−N), 24.8 (s, CH3−COO). 444 
3d: 1H NMR (400 MHz, CDCl3, 298 K): 7.93 (s, 1 H, CH7=N), 7.28 (d, JHH = 8.0 Hz, 1 H, H5), 7.04 445 
(dd, JHH = 8.0 Hz, JHH = 1.9 Hz, 1 H, H4), 6.08 (d, JHH = 1.4 Hz, 1 H, H2), 3.92 (s, 4 H, CH2 9−O + 446 
CH2 8−N), 3.64 (s, 2 H, CH2 10−O). 13C{1H} NMR (101 MHz, CDCl3, 298 K): 176.5 (s, CH7=N), 447 
159.3 (s, C1), 145.1 (s, C6), 136.2 (s, C3), 131.7 (s, C2), 128.4 (s, C5), 124.7 (s, C4), 70.6 (s, CH2 448 
10−O), 69.1 (s, CH2 9−O), 59.7 (s, CH2 8−N). 449 
4c: 1H NMR (400 MHz, CDCl3, 298 K): 7.79 (s, 1 H, CH7=N), 7.23 (d, JHH = 8.2 Hz, 1 H, H5), 6.49 450 
(d, JHH = 8.0 Hz, 1 H, H4), 5.70 (s, 1 H, H2), 3.79 (br s, 2 H, CH2 9−O), 3.66 (s, 2 H, CH2 10−O), 3.62 451 
(s, 3 H, CH3 11−O), 3.60 (br s, 2 H, CH2 8−N), 1.87 (s, 3 H, CH3−COO). 13C{1H} NMR (101 MHz, 452 
CDCl3, 298 K): 177.6 (s, CH3−COO), 175.3 (s, CH7=N), 160.0 (s, C3), 158.4 (s, C1), 153.1−152.5 (m, 453 
o-Cpy‑d5), 140.2 (s, C6), 137.8−137.2 (m, p-Cpy‑d5), 128.9 (s, C5), 124.9−124.4 (m, m-Cpy‑d5), 119.7 454 
(s, C2), 107.9 (s, C4), 70.4 (s, CH2 10−O), 68.7 (s, CH2 9−O), 58.3 (s, CH2 8−N), 54.9 (s, CH3 11−O), 455 
24.6 (s, CH3−COO). 456 
4d: 1H NMR (400 MHz, CDCl3, 298 K): 7.85 (s, 1 H, CH7=N), 7.32 (d, JHH = 8.2 Hz, 1 H, H5), 6.54 457 
(dd, JHH = 8.3 Hz, JHH = 2.1 Hz, 1 H, H4), 5.66 (d, JHH = 1.9 Hz, 1 H, H2), 3.88−3.87 (m, 4 H, CH2 458 
8−N + CH2 9−O), 3.64 (s, 2 H, CH2 10−O), 3.63 (s, 3 H, CH3 11−O). 13C{1H} NMR (101 MHz, 459 
CDCl3, 298 K): 176.1 (s, CH7=N), 160.3 (s, C3), 159.8 (s, C1), 153.0−152.4 (m, o-Cpy‑d5), 139.9 (s, 460 
C6), 137.8−137.2 (m, p-Cpy‑d5), 129.1 (s, C5), 125.1−124.6 (m, m-Cpy‑d5), 119.0 (s, C2), 108.2 (s, 461 
C4), 70.6 (s, CH2 10−O), 69.4 (s, CH2 9−O), 59.3 (s, CH2 8−N), 55.0 (s, CH3 11−O). 462 
5c: 1H NMR (400 MHz, CDCl3, 298 K): 8.06 (s, 1 H, CH7=N), 7.91 (dd, JHH = 8.2 Hz, JHH = 2.2 Hz, 463 
1 H, H4), 7.50 (d, JHH = 8.2 Hz, 1 H, H5), 6.89 (d, JHH = 2.1 Hz, 1 H, H2), 3.87−3.85 (m, 2 H, CH2 464 
9−O), 3.78−3.76 (m, 2 H, CH2 8−N), 3.67 (s, 2 H, CH2 10−O), 1.94 (s, 3 H, CH3−COO). 13C{1H} 465 
NMR (101 MHz, CDCl3, 298 K): 175.4 (s, CH7=N), 157.5 (s, C1), 152.3 (s, C6), 147.1 (s, C3), 127.5 466 
(s, C5), 126.2 (s, C2), 119.9 (s, C4), 70.3 (s, CH2 10−O), 68.2 (s, CH2 9−O), 58.5 (s, CH2 8−N), 23.7 467 
(br s, CH3−COO). 468 
5d: 1H NMR (400 MHz, CDCl3, 298 K): 8.11 (s, 1 H, CH7=N), 7.91 (dd, JHH = 8.2 Hz, JHH = 2.2 Hz, 469 
1 H, H4), 7.54 (d, JHH = 8.2 Hz, 1 H, H5), 6.94 (d, JHH = 1.8 Hz, 1 H, H2), 4.03 (br s, 2 H, CH2 8−N), 470 
3.96 (br s, 2 H, CH2 9−O), 3.66 (s, 2 H, CH2 10−O). 13C{1H} NMR (101 MHz, CDCl3, 298 K): 176.1 471 
(s, CH7=N), 158.9 (s, C1), 152.1 (s, C6), 147.4 (s, C3), 127.6 (s, C5), 125.7 (s, C2), 120.0 (s, C4), 70.8 472 
(s, CH2 10−O), 69.1 (s, CH2 9−O), 60.3 (s, CH2 8−N). 473 
6c: 1H NMR (400 MHz, CDCl3, 298 K): 8.28 (s, 1 H, CH7=N), 6.94 (dd, JHH = 8.0 Hz, JHH = 0.8 Hz, 474 
1 H, H4), 6.82 (t, JHH = 7.8 Hz, 1 H, H3), 6.05 (dd, JHH = 7.6 Hz, JHH = 0.7 Hz, 1 H, H2), 3.83 (br s, 475 
2 H, CH2 9−O), 3.69 (s, 2 H, CH2 10−O), 3.68 (br s, 2 H, CH2 8−N), 1.87 (s, 3 H, CH3−COO). 476 
13C{1H} NMR (101 MHz, CDCl3, 298 K): 177.8 (s, CH3−COO), 174.6 (s, CH7=N), 158.2 (s, C1), 477 
144.0 (s, C6), 131.6 (s, C5), 131.5 (s, C3), 131.0 (s, C2), 124.8 (s, C4), 70.4 (s, CH2 10−O), 68.3 (s, 478 
CH2 9−O), 59.0 (s, CH2 8−N), 24.6 (s, CH3−COO). 479 
6d: 1H NMR (400 MHz, CDCl3, 298 K): 8.29 (s, 1 H, CH7=N), 6.98 (d, JHH = 7.9 Hz, 1 H, H4), 6.85 480 
(t, JHH = 7.8 Hz, 1 H, H3), 6.00 (d, JHH = 7.2 Hz, 1 H, H2), 3.93 (s, 4 H, CH2 9−O + CH2 8−N), 3.68 481 
(s, 2 H, CH2 10−O). 13C{1H} NMR (101 MHz, CDCl3, 298 K): 175.5 (s, CH7=N), 159.5 (s, C1), 482 
143.9 (s, C6), 131.9 (s, C5), 131.8 (s, C3), 130.3 (s, C2), 125.2 (s, C4), 70.3 (s, CH2 10−O), 68.9 (s, 483 
CH2 9−O), 60.0 (s, CH2 8−N).  484 
Synthesis of Compounds e. 3e: A stirred suspension of chloridobridged compound 3b (124 mg, 0.09 485 
mmol) in chloroform (ca. 30 mL) was treated with small portions of triphenylphosphane (total addition: 486 
98 mg, 0.37 mmol). After 3 h of stirring at room temperature, the resultant solution was filtered and 487 
evaporated under vacuum. Crude was purified by column chromatography over silica gel in order to 488 
remove the free phosphane excess (Φ = 2.5 cm × 18 cm). Elution was performed using a solvent system 489 
with a gradient of increasing polarity from chloroform to 100:2 chloroform/methanol. The yellow band 490 
was evaporated in vacuo. Addition of diethyl ether (ca. 5 mL) resulted in the formation of a pale yellow 491 
solid, which was next filtered off and air-dried (73 mg, 33% yield). 1H NMR (400 MHz, CDCl3, 298 492 
K): 8.08 (d, JHP = 8.0 Hz, 1 H, CH7=N), 7.74−7.69 (m, 6 H, o-C6H5), 7.47−7.42 (m, 3 H, p-C6H5), 493 
7.38 (td, JHH = 7.2 Hz, JHP = 2.2 Hz, 6 H, m-C6H5), 7.17 (d, JHH = 8.0 Hz, 1 H, H5), 6.83 (dd, JHH = 494 
8.0 Hz, JHH = 1.9 Hz, 1 H, H4), 6.23 (dd, JHP = 5.8 Hz, JHH = 1.9 Hz, 1 H, H2), 4.03 (dd, JHH = 8.9 495 
Hz, JHH = 4.4 Hz, 2 H, CH2 8−N), 3.86−3.84 (m, 2 H, CH2 9−O), 3.63 (s, 2 H, CH2 10−O). 13C{1H} 496 
NMR (101 MHz, CDCl3, 298 K): 176.3 (d, JCP = 4.1 Hz, CH7=N), 159.5 (s, C1), 146.5 (s, C6), 137.4 497 
(d, JCP = 10.6 Hz, C2), 135.7 (d, JCP = 7.0 Hz, C3), 135.3 (d, JCP = 11.7 Hz, o-C6H5), 130.9 (d, JCP = 498 
2.5 Hz, p- C6H5), 130.4 (d, JCP = 50.9 Hz, i-C6H5), 128.7 (s, C5), 128.2 (d, JCP = 11.0 Hz, m-C6H5), 499 
124.1 (s, C4), 70.5 (s, CH2 10−O), 69.6 (s, CH2 9−O), 58.2 (s, CH2 8−N). 31P{1H} NMR (101 MHz, 500 
CHCl3, 298 K): 40.0 (s). IR (cm−1): 1621 (C=N st), 1095 (q, X-sens.), 532 (y, Xsens.), 512 (y, X-sens.), 501 
496 (y, X-sens.). MS-MALDI TOF (+) (DHB), m/z: 898.6 (calcd 899.0) [M − Cl − PPh3]+, 636.4 (calcd 502 
636.9) [M − Cl−2 PPh3]+. Anal. Calcd for C56H50Cl4N2O2P2Pd2 (Mr 1199.61): C 56.07, H 4.20, N 503 
2.34. Found: C 55.5, H 4.2, N 2.3. 504 
4e: A flask loaded with chlorido-bridged complex 4b (38 mg, 0.03 mmol), triphenylphosphane (29 mg, 505 
0.11 mmol), and chloroform (20 mL) was maintained under constant stirring for 30 min. During this 506 
time, the yellow solution became nearly colorless. Evaporation of the solvent followed by addition of 507 
diethyl ether (ca. 5 mL) furnished the required product, which was then filtered off and air-dried (60 mg, 508 
88% yield). 1H NMR (400 MHz, CDCl3, 298 K): 8.03 (d, JHP = 8.2 Hz, 1 H, CH7=N), 7.76−7.71 (m, 6 509 
H, o-C6H5), 7.45−7.40 (m, 3 H, p-C6H5), 7.38−7.34 (m, 6 H, m-C6H5), 7.19 (d, JHH = 8.3 Hz, 1 H, 510 
H5), 6.38 (dd, JHH = 8.3 Hz, JHH = 2.4 Hz, 1 H, H4), 5.96 (dd, JHP = 6.4 Hz, JHH = 2.3 Hz, 1 H, H2), 511 
4.01−3.97 (m, 2 H, CH2 8−N), 3.85−3.83 (m, 2 H, CH2 9−O), 3.64 (s, 2 H, CH2 10−O), 2.96 (s, CH3 512 
11−O). 13C{1H} NMR (101 MHz, CDCl3, 298 K): 176.2 (d, JCP = 3.8 Hz, CH7=N), 160.7 (s, C1), 513 
159.5 (d, JCP = 6.3 Hz, C3), 141.0 (s, C6), 135.4 (d, JCP = 11.9 Hz, o-C6H5), 131.1 (d, JCP = 50.0 Hz, 514 
i-C6H5), 130.8 (d, JCP = 1.9 Hz, p-C6H5), 129.2 (s, C5), 128.1 (d, JCP = 10.8 Hz, m-C6H5), 123.1 (d, 515 
JCP = 11.4 Hz, C2), 110.8 (s, C4), 70.4 (s, CH2 10−O), 69.9 (s, CH2 9−O), 57.9 (s, CH2 8−N), 54.6 (s, 516 
CH3 11−O). 31P{1H} NMR (101 MHz, acetone-d6, 298 K): 41.6 (s). IR (cm−1): 1620 (C=N st), 517 
1234/1217 (CH3−O−Car as st, split), 1096 (q, Xsens.), 1027 (CH3−O−Car sym st), 531 (y, X-sens.), 518 
513 (y, X-sens.), 502 (y, X-sens.). MS-MALDI TOF (+) (DHB), m/z: 628.5 (calcd 629.0) [M − Cl−2 519 
PPh3]+. Anal. Calcd for C58H56Cl2N2O4P2Pd2 (Mr 1190.77): C 58.50, H 4.74, N 2.35. Found: C 520 
58.3, H 4.7, N 2.1. 521 
5e: To a suspension of chlorido-bridged complex 5b (49 mg, 0.03 mmol) in acetone (25 mL) was added 522 
triphenylphosphane (35 mg, 0.13 mmol). The mixture was stirred for 1 h at room temperature. After 523 
evaporation of the solvent, the mixture was then subjected to column chromatography over silica gel (Φ 524 
= 2.5 cm × 29 cm) using a 100:60 ethyl acetate/hexane solvent system. Eluent polarity was gradually 525 
increased to 100:30, and finally ethyl acetate was employed. The target product was obtained after 526 
solvent removal followed by addition of diethyl ether (ca. 5 mL). The pale yellow precipitate was 527 
separated by filtration and air-dried (39 mg, 45% yield). 1H NMR (400 MHz, CDCl3, 298 K): 8.25 (d, 528 
JHP = 7.9 Hz, 1 H, CH7=N), 7.74−7.68 (m, 7 H, o-C6H5 + H4), 7.47−7.36 (m, 10 H, p-C6H5 + H5 + 529 
m- C6H5), 7.24 (dd, 1 H, JHP = 5.8 Hz, JHH = 2.1 Hz, H2), 4.14−4.10 (m, 2 H, CH2 8−N), 3.91−3.89 530 
(m, 2 H, CH2 9−O), 3.64 (s, 2 H, CH2 10−O). 13C{1H} NMR (101 MHz, CDCl3, 298 K): 175.8 (d, 531 
JCP = 4.2 Hz, CH7=N), 159.4 (s, C1), 153.7 (s, C6), 146.8 (d, JCP = 5.8 Hz, C3), 135.2 (d, JCP = 11.7 532 
Hz, o-C6H5), 131.4 (d, JCP = 11.6 Hz, C2), 131.2 (d, JCP = 2.3 Hz, p-C6H5), 129.8 (d, JCP = 52.0 Hz, 533 
i-C6H5), 128.4 (d, JCP = 11.1 Hz, m-C6H5), 127.9 (s, C5), 119.4 (s, C4), 70.7 (s, CH2 10−O), 69.5 (s, 534 
CH2 9−O), 58.7 (s, CH2 8−N). 31P{1H} NMR (121 MHz, CDCl3, 298 K): 39.8 (s). IR (cm−1): 1628 535 
(CN st), 1517 (NO2 as st), 1339 (NO2 sym st), 1098 (q, X-sens.), 533 (y, X-sens.), 512 (y, Xsens.), 536 
500 (y, X-sens.). MS-MALDI TOF (+) (DTH), m/z: 921.2 (calcd 921.0) [M − Cl − PPh3]+, 659.0 (calcd 537 
658.9) [M − Cl−2 PPh3]+. Anal. Calcd for C56H50Cl2N4O6P2Pd2 (Mr 1220.71): C 55.10, H 4.13, N 538 
4.59. Found: C 55.5, H 4.1, N 4.5. 539 
6e: Chlorido-bridged complex 6b (60 mg, 0.04 mmol) and triphenylphosphane (46 mg, 0.17 mmol) were 540 
combined in chloroform (20 mL). After 30 min of stirring at room temperature, the solution obtained 541 
was concentrated to dryness using a rotatory evaporator. Addition of diethyl ether (ca. 5 mL) furnished 542 
the desired product as a cream-colored powder, which was collected by filtration and dried in air (85 543 
mg, 81% yield). 1H NMR (400 MHz, CDCl3, 298 K): 8.61 (d, JHP = 8.6 Hz, 1 H, CH7=N), 7.74−7.69 544 
(m, 6 H, o- C6H5), 7.45−7.42 (m, 3 H, p-C6H5), 7.36 (td, JHH = 8.0 Hz, JHP = 2.0 Hz, 6 H, m-C6H5), 545 
6.81 (d, JHH = 8.0 Hz, 1 H, H4), 6.43 (t, JHH = 7.8 Hz, 1 H, H3), 6.26 (apparent t, JHH + JHP ≈ 6.8 Hz, 546 
1 H, H2), 4.10−4.05 (m, 2 H, CH2 8−N), 3.86 (m, 2 H, CH2 9−O), 3.69 (s, 2 H, CH2 10−O). 13C{1H} 547 
NMR (101 MHz, CDCl3, 298 K): 175.4 (d, JCP = 4.3 Hz, CH7=N), 160.0 (s, C1), 145.0 (s, C6), 136.6 548 
(d, JCP = 10.6 Hz, C2), 135.4 (d, JCP = 11.9 Hz, o-C6H5), 132.0 (s, C5), 131.2 (d, JCP = 5.7 Hz, C3), 549 
130.9 (d, JCP = 2.4 Hz, p-C6H5), 130.8 (d, JCP = 50.8 Hz, i-C6H5), 128.1 (d, JCP = 11.0 Hz, m-550 
C6H5), 124.9 (s, C4), 70.3 (s, CH2 10−O), 69.5 (s, CH2 9−O), 58.5 (s, CH2 8−N). 31P{1H} NMR (101 551 
MHz, CHCl3, 298 K): 41.2 (s). IR (cm−1): 1620 (C=N st), 1097 (q, X-sens.), 533 (y, X-sens.), 513 (y, 552 
X-sens.), 503 (y, X-sens.). MS-MALDI TOF (+) (DHB), m/z: 898.9 (calcd 899.0) [M − Cl −PPh3]+, 553 
636.9 (calcd 636.9) [M − Cl−2 PPh3]+. Anal. Calcd for C56H50Cl4N2O2P2Pd2 (Mr 1199.61): C 554 
56.07, H 4.20, N 2.34. Found: C 55.8, H 4.2, N 2.3. 555 
Synthesis of Compound 3f. To a stirred suspension of chloridobridged complex 3b (193 mg, 0.14 556 
mmol) in chloroform (ca. 25 mL) was added 2,2′-(ethylenedioxy)bis(ethylamine) (42 mg, 0.28 mmol). 557 
The reaction mixture was allowed to stir for 4 h at room temperature, after which time the suspension 558 
obtained was reduced under vacuum. Addition of a mixture of diethyl ether/hexanes (ca. 7 mL) yielded 559 
the product 3f as a yellow-colored solid, which was filtered off and airdried (212 mg, 91% yield). 1H 560 
NMR (500 MHz, CDCl3, 298 K): 7.90 (s, 1 H, CH7=N), 7.30 (d, JHH = 8.0 Hz, 1 H, H5), 7.15 (dd, 561 
JHH = 8.0 Hz, JHH = 1.9 Hz, 1 H, H4), 7.03 (d, JHH = 1.9 Hz, 1 H, H2), 3.82 (s, 2 H, CH2 13−O), 562 
3.81−3.77 (m, 2 H, CH2 9−O), 3.71−3.67 (m, 4 H, CH2 8−N + CH212−O), 3.63 (s, 2 H, CH2 10−O), 563 
3.15−3.11 (br m, 2 H, CH2 1−NH2), 3.04−3.02 (br m, 2 H, NH2). 13C{1H} NMR (101 MHz, CDCl3, 564 
298 K): 175.4 (s, CH7=N), 157.9 (s, C1), 145.7 (s, C6), 135.8 (s, C3), 130.1 (s, C2), 128.9 (s, C5), 125.1 565 
(s, C4), 71.4 (s, CH2 13−O), 71.2 (s, CH2 12−O), 70.3 (s, CH2 10−O), 68.9 (s, CH2 9−O), 59.0 (s, CH2 566 
8−N), 45.8 (s, CH2 11−NH2). IR (cm−1): 3225 (NH2 as st), 3143 (NH2 sym st), 1617 (C=N st). 567 
HRMS-ESI (+) (H2O/CH3CN (1:1)), m/z: 867.0445 (calcd 867.0402) [M − Cl + 2 CH3CN]+, 826.0185 568 
(calcd 826.0137) [M − Cl + CH3CN]+, 784.9872 (calcd 784.9872) [M − Cl]+, 636.8655 (calcd 569 
636.8660) [M − Cl − (NN)]+. 570 
Biological Studies. Cell Culture. Breast cancer (MCF-7 and MBAMD-231) and colon cancer (HCT116) 571 
cells were grown as a monolayer culture in minimum essential medium (DMEM with Lglutamine, 572 
without glucose, and without sodium pyruvate) in the presence of 10% heat-inactivated fetal calf serum, 573 
10 mM D-glucose, and 0.1% streptomycin/penicillin, in standard culture conditions (humidified air with 574 
5% CO2 at 37 °C). 575 
Cell Viability Assay. A stock solution (50 mM) of each compound was prepared in high-purity DMSO. 576 
Then, serial dilutions were made with DMSO (1:1), and finally a 1:500 dilution of the diluted solutions 577 
of compounds on cell media was prepared. In this way DMSO concentration in cell media was always 578 
the same. The assay was performed as described by Givens et al.25 MDA-MB231 and MCF7 cells were 579 
plated at 5000 cells/well, respectively, in 100 mL of media in 96-well tissue culture plates (Cultek). 580 
After 24 h, media was replaced by 100 mL/well of drug serial dilutions. Control wells did not contain 581 
any complex. Each point concentration was run in triplicate. Reagent blanks, containing media and 582 
colorimetric reagent without cells, were run on each plate. Blank values were subtracted from test values 583 
and were routinely 5−10% of the control values. Plates were incubated 72 h. Hexosaminidase activity 584 
was measured according to the following protocol. The media was removed, and cells were washed once 585 
with PBS. Then, 60 mL of substrate solution (p-nitrophenol-N-acetyl-b-Dglucosamide 7.5 mM, sodium 586 
citrate 0.1 M at pH 5.0, and 0.25% Triton X-100) was added to each well and incubated at 37 °C for 1−2 587 
h. After this incubation time, a bright yellow solid appeared. Then, the plates were developed by adding 588 
90 mL of developer solution (glycine 50 mM, pH 10.4; EDTA 5 mM), and the absorbance was recorded 589 
at 410 nm.  590 
DNA Migration Studies. A stock solution (10 mM) of each compound was prepared in high-purity 591 
DMSO. Then, serial dilutions were made in Milli-Q water (1:1). Plasmid pBluescript SK+ (Stratagene) 592 
was obtained using QIAGEN plasmid midi kit as described by the manufacturer. Interaction of drugs 593 
with pBluescript SK+ plasmid DNA was analyzed by agarose gel electrophoresis following a 594 
modification of the method described by Abdullah et al.26 Plasmid DNA aliquots (40 μg mL−1) were 595 
incubated in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) with different concentrations of 596 
compounds 1a, 1b, 1e, 3a, 3b, 3e, and 3f ranging from 0 to 200 μM at 37 °C for 24 h. The final DMSO 597 
concentration in the reactions was always lower than 1%. For comparison, cisplatin and ethidium 598 
bromide were used as reference controls. Aliquots of 20 μL of the incubated solutions of compounds 599 
containing 0.8 μg of DNA were subjected to 1% agarose gel electrophoresis in TAE buffer (40 mM 600 
Tris-acetate, 2 mM EDTA, pH 8.0). The gel was stained in TAE buffer containing ethidium bromide 601 
(0.5 mg mL−1) and visualized and photographed under UV light. 602 
Topoisomerase I-based experiments were performed as described previously.20 Supercoiled pBluescript 603 
DNA, obtained as described above, was treated with topisomerase I in the absence or presence of 604 
increasing concentrations of compound 3e. Assay mixtures contained supercoiled pBluescript DNA (0.8 605 
μg), calf thymus topoisomerase I (3 units), and complex 3e (0−200 μM) in 20 μL of Tris−HCl buffer (Ph 606 
7.5) containing 175 mM KCl, 5 mM MgCl2, and 0.1 mM EDTA. Ethidium bromide (10 μM) was used 607 
as a control of intercalating agents. Reactions were incubated for 30 min at 37 °C and stopped by the 608 
addition of 2 μL of agarose gel loading buffer. Samples were then subjected to electrophoresis and DNA 609 
bands stained with ethidium bromide as described above. 610 
Computational Details. Molecular dynamics simulations were conducted using the MM3 force 611 
field27,28 as implemented by the CAChe program (version 7.5.0.85).29 All DFT calculations were 612 
carried out with the GAUSSIAN 03 package of programs30 using the B3LYP hybrid functional.31,32 613 
The basis set was chosen as follows: LANL2DZ33,34 was used for palladium with an effective core 614 
potential to replace the 36 innermost electrons of Pd; for H, C, N, O, and Cl the 6-31G(d) basis set 615 
including polarization functions for non-hydrogen atoms was used.35,36 Solvent effects were taken into 616 
account using the CPCM model.37 PM6 calculations38 were performed using the Spartan ’14 617 
software.39 618 
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Legends to figures 776 
 777 
Chart 1 Structural Formula of BBR3464 778 
 779 
Figure 1. Molecular crystal structure of 1d·3(CDCl3). Hydrogen and deuterium atoms have been 780 
omitted for clarity. Selected bond lengths (Å) and bond angles (deg): Pd(1)−C(1) = 1.998(4), 781 
Pd(1)−N(1) = 2.029(5), Pd(1)−N(2) = 2.046(5), Pd(1)−Cl(1) = 2.4099(14), N(1)−C(7) = 1.276(7), 782 
C(1)−Pd(1)−N(1) = 80.74(18), N(1)− Pd(1)−Cl(1) = 96.39(13), Cl(1)−Pd(1)−N(2) = 88.76(11), 783 
N(2)−Pd(1)−C(1) = 94.38(16).. 784 
 785 
Figure 2. Molecular crystal structure of 2d·2(CDCl3). Hydrogen and deuterium atoms have been 786 
omitted for clarity. Selected bond lengths (Å) and bond angles (deg): Pd(1)−C(1) = 2.008(5), 787 
Pd(1)−N(1) = 2.034(4), Pd(1)−N(2) = 2.052(4), Pd(1)−Cl(1) = 2.4099(16), N(1)−C(7) = 1.297(7), 788 
C(1)−Pd(1)−N(1) = 82.3(2), N(1)−Pd(1)−Cl(1) = 95.59(14), Cl(1)−Pd(1)−N(2) = 88.96(12), 789 
N(2)−Pd(1)−C(1) = 93.17(18). 790 
 791 
Figure 3. Molecular crystal structure of 1e·4(CDCl3). Hydrogen atoms have been omitted for clarity. 792 
Selected bond lengths (Å) and bond angles (deg): Pd(1)−C(1) = 2.065(4), Pd(1)−N(1) = 2.127(3), 793 
Pd(1)−P(1) = 2.2833(12), Pd(1)−Cl(1) = 2.3779(17), N(1)−C(7) = 1.222(5), C(1)−Pd(1)−N(1) = 794 
80.44(14), N(1)−Pd(1)−Cl(1) = 91.68(9), Cl(1)−Pd(1)−P(1) = 93.42(5), P(1)−Pd(1)−C(1) = 94.49(12). 795 
 796 
Chart 2. Proposed Structure for Compound 3f and Labeling of the Protons 797 
 798 
Figure 4. DFT-optimized structure for the dinuclear form of compound 3f. 799 
 800 
Figure 5. DFT-optimized structure for the tetranuclear form of compound 3f. 801 
 802 
Figure 6. Inhibition of cell growth proliferation for human adenocarcinoma colon (HCT116) and breast 803 
(MDA-MB231 and MCF7) cell lines after 72 h of exposure to compounds 3a, 3b, 3e, and 3f and 804 
cisplatin. 805 
 806 
Figure 7. 7. Interaction of pBluescript SK+ plasmid DNA (0.8 μg) with increasing concentrations of 807 
compounds 1a, 1b, 1e, 3a, 3b, 3e, 3f, cisplatin, and ethidium bromide (EtBr). Lane 1: DNA only. Lane 808 
2: 2.5 μM. Lane 3: 5 μM. Lane 4: 10 μM. Lane 5: 25 μM. Lane 6: 50 μM. Lane 7: 100 μM. Lane 8: 200 809 
μM. ccc = supercoiled closed circular DNA; oc = open circular DNA. 810 
 811 
 812 
Figure 8. Analysis of 3e as a putative DNA intercalator or topoisomerase I inhibitor. Conversion of 813 
supercoiled pBluescript plasmid DNA (0.8 μg) to relaxed DNA by the action of topoisomerase I (3 814 
units) in the absence or in the presence of increasing amounts of compound 3e was analyzed by agarose 815 
gel electrophoresis. Negative and positive intercalator controls, etoposide (Etop, 100 μM) and ethidium 816 
bromide (EtBr, 10 μM), are also shown. Lane 1, DNA only. Lane 2, 0 μM compound. Lane 3, 10 μM. 817 
Lane 4, 25 μM. Lane 5, 50 μM. Lane 6, 100 μM. Lane 7, 200 μM. Except for lane 1, all lanes included 818 
topomerase I. ccc = supercoiled closed circular DNA form. Oc = open circular DNA form. 819 
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a Conditions: (i) Pd(OAc)2, toluene, 60 °C for 1a, 2a, and 3a; Pd(OAc)2, acetic acid, 60 °C for 4a and 835 
5a; Pd(OAc)2, acetic acid, room temperature for 6a. (ii) LiCl (excess), acetone, or a mixture of 836 
chloroform/acetone, room temperature. (iii) L = py-d5: py-d5, CDCl3, room temperature, L = PPh3: 837 
molar ratio PPh3/b (n =1) = 2:1, acetone or chloroform, room temperature 838 
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FIGURE 6 873 
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Table 1. IC50 (μM) for Compounds 1a, 1b, 1e, 3a, 3b, 3e, 3f, and Cisplatina 887 
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